What Semax is. And where it comes from
Semax is a synthetic heptapeptide based on the ACTH(4-10) fragment, the portion of adrenocorticotropic hormone that retains neurotropic activity without the hormonal (adrenal cortex stimulating) effects of full-length ACTH. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and has been approved in Russia since the mid-1990s.
It is administered as a nasal spray. The molecule was specifically engineered with a Pro-Gly-Pro C-terminal extension to resist enzymatic degradation and extend its half-life compared to the native ACTH fragment.
Semax is one of the few nootropic peptides with actual regulatory approval anywhere in the world, but that approval is Russian, and the clinical data sits mostly in Russian-language journals. That does not make it invalid, but it does make independent verification harder.
Mechanism, in plain English
The published literature points to several neurological pathways that Semax influences. These are consistently reported across both animal and human studies in the Russian literature.
Want all 23 cognitive enhancement compounds in one place?
The Peptexa Cognitive Enhancement guide covers every compound in this category, mechanism, evidence level, and regulatory status for each.
What the human evidence shows
Unlike many research peptides, Semax has published human clinical data. Studies in Russian medical journals report efficacy for acute ischemic stroke recovery (improved neurological outcomes when administered within 6 hours), cognitive enhancement in healthy subjects (attention and memory tasks), and optic nerve disease (improved visual function).
The most-cited review of the clinical evidence is Ashmarin et al. (2007). Additional clinical reports exist for anxiety, adaptive stress response, and ADHD-related symptoms in children.
The critical caveat: most of this data comes from Russian research groups, often without placebo controls that meet Western RCT standards. Independent Western replication of these findings is limited. The signal is real, but the evidence level is ★★★☆☆, preliminary human evidence.
Semax has more published human data than most peptides in the nootropic space. The issue is not the absence of human studies, it is the absence of independent Western replication of those studies.
Regulatory status
Semax is not FDA-approved in the United States for any indication. It is classified as a research compound in the US market.
In Russia, Semax has been approved since the mid-1990s and is available as a prescription nasal spray for neuroprotection following stroke and for cognitive enhancement. It is listed in the Russian State Register of Medicines. Some CIS countries also recognize the Russian approval. Last reviewed 2026-08-19.
Common synonyms researchers use
Semax · ACTH(4-10)-Pro-Gly-Pro · Heptapeptide · ACTH 4-10 analog. Also referenced in literature as the "Semax nootropic peptide" or "neuropeptide Semax."
Safety & adverse-event landscape
In the published Russian clinical literature, Semax administered intranasally has been reported with a favorable safety profile across multiple studies. Side effects are described as rare and mild, primarily nasal irritation at the application site. No significant systemic adverse events have been consistently reported in the published human data.
However, long-term safety data from Western-standard monitoring is not available. As with any compound that modulates neurotransmitter systems, theoretical interactions with psychiatric medications (SSRIs, MAOIs, stimulants) should be considered. Consult your provider.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision involving a peptide or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The full Cognitive Enhancement reference
23 compounds. Mechanism, evidence level, and regulatory status for every one.
Get the Cognitive Enhancement Guide →